Kulabaş S., İpek H., Tüfekçi A. R., Demirtaş İ., Tümer T.

5th International Conference on Natural Product Utilization, Varna, Bulgaria, 30 May - 02 June 2023, pp.197

  • Publication Type: Conference Paper / Summary Text
  • City: Varna
  • Country: Bulgaria
  • Page Numbers: pp.197
  • Çanakkale Onsekiz Mart University Affiliated: Yes


Bioactivity guided fractionation of ethyl acetate extract obtained from Lavandula stoechas L. (L. stoechas) leaded to several known phenolics: Rosmarinic acid (RA), Caffeic acid (CA), Luteolin (LUT), Propanoic acid methyl ester (PAME), Luteolin 7 glucoside (L7G), Apigenin-7-glucoside (A7G) and one unusual hybrid compound RA-CA (Caffeoyl rosmarinic acid) [1].  All these compounds were investigated for their inhibitory effects on hepatic glucose output and mechanism of action.
The effects of bioactive compounds on glucose production (GP) was determined by measuring the amount of glucose released from hepatic cells under starvation conditions. The mRNA levels of PEPCK and G6Pase enzymes, the main regulators of gluconeogenesis, were determined by qPCR analysis. The potentials of the compounds to suppress glycerol release from adipocytes were determined by measuring the amount of glycerol in the medium.

RA, CA, LUT, PAME, L7G, A7G, RA-CA, BA at 50 µM doses suppressed 8-CTP-Dex-induced GP by 59%, 60%, 30%, 73%, 27%, 56%, 76%, and 22%, respectively (p<0.05). LUT, PAME, RA-CA at 50 µM dose suppressed 8-CTP-Dex-induced G6Pase mRNA levels by 95%, 53%, and 22%, LUT downregulated 8-CTP-Dex-induced PEPCK mRNA level by 84%, respectively(p<0.05).

In case of insulin resistance, increased level of triglyceride lipolysis in adipocytes delivers elevated fatty acid and glycerol to the liver. While the former condition contributes to  hepatosteatosis the later event increases rate of gluconeogenesis leading to hyperglycemia. LUT, PAME, A7G, RA-CA at 50 µM doses demonstrated supressing effects (12%, 21%, 37%, respectively) on glycerol release in isoproterenol induced adipocytes. Therefore, L.stoechas has biologically potent compounds against insulin resistance.  

*TUBITAK Project ID: 112T442